Vince Holding: Q1 Earnings Insights

  Vince Holding (NYSE:VNCE) reported its Q1 earnings results on Thursday, June 9, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

 

Vince Holding (NYSE:VNCE) reported its Q1 earnings results on Thursday, June 9, 2022 at 07:30 AM.

Here’s what investors need to know about the announcement.

Earnings

Vince Holding beat estimated earnings by 10.45%, reporting an EPS of $-0.6 versus an estimate of $-0.67.

Revenue was up $20.84 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.16 which was followed by a 4.23% increase in the share price the next day.

Here’s a look at Vince Holding’s past performance:

 

Quarter Q4 2021 Q3 2021 Q2 2021 Q1 2021
EPS Estimate -0.07   -0.64 -0.64
EPS Actual -0.23 0.18 -0.05 -0.98
Revenue Estimate 92.40M 94.90M 70.60M 57.50M
Revenue Actual 99.03M 87.45M 78.67M 57.53M

To track all earnings releases for Vince Holding visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Ascendis Pharma Announced Once-Weekly TransCon CNP Achieved Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years

Ascendis Pharma A/S (Nasdaq: ASND) today announced positive topline results from the ACcomplisH Trial, its Phase 2 randomized, double-blind, placebo-controlled, dose-escalation trial evaluating the safety and efficacy of once-weekly TransCon CNP compared to placebo in children with achondroplasia aged 2 to 10 years old.

ASND